Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zevra Therapeutics (ZVRA – Research Report), Masimo (MASI – Research Report) and Taysha Gene Therapies (TSHA – Research Report).
Zevra Therapeutics (ZVRA)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Zevra Therapeutics yesterday and set a price target of $12.00. The company’s shares closed last Wednesday at $6.15.
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of
Zevra Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $18.25, representing a 196.7% upside. In a report issued on January 8, Canaccord Genuity also maintained a Buy rating on the stock with a $24.00 price target.
See the top stocks recommended by analysts >>
Masimo (MASI)
In a report released today, Michael Matson from Needham maintained a Hold rating on Masimo. The company’s shares closed last Wednesday at $116.46.
According to TipRanks.com, Matson is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Masimo with a $93.60 average price target, a -17.4% downside from current levels. In a report issued on December 26, Wells Fargo also maintained a Hold rating on the stock with a $81.00 price target.
Taysha Gene Therapies (TSHA)
In a report released today, Gil Blum from Needham maintained a Buy rating on Taysha Gene Therapies, with a price target of $5.00. The company’s shares closed last Wednesday at $1.88.
According to TipRanks.com, Blum is a 4-star analyst with an average return of
Currently, the analyst consensus on Taysha Gene Therapies is a Strong Buy with an average price target of $5.94.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ZVRA:
- Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
- Zevra Therapeutics announces FDA acceptance of resubmission of arimoclomol NDA
- Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer
- Zevra Therapeutics appoints Adrian Quartel as CMO
- Zevra Therapeutics price target raised to $15 from $10 at H.C. Wainwright
